Stereoselective synthesis of the two major metabolites of spironolactone, 3α- and 3β-hydroxy-7α-methylthio-17α-pregn-4-ene-21,17-carbolactoneGUO LI; YAN ZHANG.Steroids. 2007, Vol 72, Num 6-7, pp 569-572, issn 0039-128X, 4 p.Article

Spironolactone-Loaded Liposomes Produced Using a Membrane Contactor Method: An Improvement of the Ethanol Injection TechniqueLAOUINI, A; JAAFAR-MAALEJ, C; GANDOURA-SFAR, S et al.Progress in colloid & polymer science. 2012, Vol 139, pp 23-28, issn 0340-255X, isbn 978-3-642-28973-6, 1Vol, 6 p.Conference Paper

Protective effect of spironolactone on endothelial cell apoptosisWILLIAMS, Tracy A; VERHOVEZ, Andrea; MILAN, Alberto et al.Endocrinology (Philadelphia). 2006, Vol 147, Num 5, pp 2496-2505, issn 0013-7227, 10 p.Article

Simultaneous kinetic spectrophotometric determination of spironolactone and canrenone in urine using partial least-squares regressionMARTIN, E; JIMENEZ, A. I; HERNANDEZ, O et al.Talanta (Oxford). 1999, Vol 49, Num 1, pp 143-154, issn 0039-9140Article

Increasing Exposure to Drug-Drug Interactions Between 1992 and 2005 in People Aged ≥55 YearsBECKER, Matthijs L; VISSER, Loes E; VAN GELDER, Teun et al.Drugs & aging. 2008, Vol 25, Num 2, pp 145-152, issn 1170-229X, 8 p.Article

Treatment of heart failure with spironolactone -trial and tribulationsMCMURRAY, John J. V; O'MEARA, Eileen.The New England journal of medicine. 2004, Vol 351, Num 6, pp 526-528, issn 0028-4793, 3 p.Article

Preparation and characterization of spironolactone-loaded nanocapsules for paediatric useLIMAYEM BLOUZA, I; CHARCOSSET, C; SFAR, S et al.International journal of pharmaceutics. 2006, Vol 325, Num 1-2, pp 124-131, issn 0378-5173, 8 p.Article

Isolation and identification of novel impurities in spironolactoneHUA CHEN; WANG, You-Fu; YANG, Zhong-Duo et al.Journal of pharmaceutical and biomedical analysis. 2006, Vol 40, Num 5, pp 1263-1267, issn 0731-7085, 5 p.Article

Long-Term Effects of Spironolactone in Peritoneal Dialysis PatientsITO, Yasuhiko; MIZUNO, Masashi; YUZAWA, Yukio et al.Journal of the American Society of Nephrology. 2014, Vol 25, Num 5, pp 1094-1102, issn 1046-6673, 9 p.Article

Comparison of the efficacy of 5% topical spironolactone gel and placebo in the treatment of mild and moderate acne vulgaris: a randomized controlled trialBAHARE MALEK AFZALI; YAGHOOBI, Elena; YAGHOOBI, Reza et al.Journal of dermatological treatment. 2012, Vol 23, Num 1, pp 21-25, issn 0954-6634, 5 p.Article

Rapid, dynamic changes in glomerular permeability to macromolecules during systemic angiotensin II (ANG II) infusion in ratsAXELSSON, Josefin; RIPPE, Anna; OBERG, Carl M et al.American journal of physiology. Renal physiology. 2012, Vol 72, Num 3, issn 1931-857X, F790-F799Article

The Effect of Spironolactone on Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter-DefibrillatorsZARRAGA, Ignatius Gerardo E; DOUGHERTY, Cynthia M; MACMURDY, Karen S et al.Circulation. Arrhythmia and electrophysiology. 2012, Vol 5, Num 4, pp 739-747, issn 1941-3149, 9 p.Article

Beneficial effects of hydrocortisone or spironolactone coating on foreign body response to mesh biomaterial in a mouse modelBRANDT, Christopher J; KAMMER, Daniel; FIEBELER, Anette et al.Journal of biomedical materials research. Part A. 2011, Vol 99, Num 3, pp 335-343, issn 1549-3296, 9 p.Article

Matrix metalloproteinase 2 induces epithelial-mesenchymal transition in proximal tubules from the luminal side and progresses fibrosis in mineralocorticoid/salt-induced hypertensive ratsIWAZU, Yoshitaka; MUTO, Shigeaki; HIRAHARA, Ichiro et al.Journal of hypertension. 2011, Vol 29, Num 12, pp 2440-2453, issn 0263-6352, 14 p.Article

Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fractionDESAI, Akshay S; LEWIS, Eldrin F; MCKINLAY, Sonja et al.The American heart journal. 2011, Vol 162, Num 6, pp 966-972, issn 0002-8703, 7 p.Article

Physiology of aldosterone and pharmacology of aldosterone blockersSTRUTHERS, Allan D; UNGER, Thomas.European heart journal supplements. 2011, Vol 13, Num B, issn 1520-765X, B27-B30Article

Safety aspects of aldosterone-blocking drugsRUILOPE, Luis M.European heart journal supplements. 2011, Vol 13, Num B, issn 1520-765X, B40-B42Article

Pathogenesis of Hypertension: Interactions Among Sodium, Potassium, and AldosteroneBÜSSEMAKER, Eckhart; HILLEBRAND, Uta; HAUSBERG, Martin et al.American journal of kidney diseases. 2010, Vol 55, Num 6, pp 1111-1120, issn 0272-6386, 10 p.Article

The effect of spironolactone on sweat and urinary sodium excretion during exercise in humansLEE, Nanette V. L; MILLER, Paul W; BUONO, Michael J et al.Clinical physiology and functional imaging (Print). 2010, Vol 30, Num 1, pp 13-16, issn 1475-0961, 4 p.Article

Synthesis and Micellization of Linear-Dendritic Copolymers and Their Solubilization Ability for Poorly Water-Soluble DrugsZHENGYUAN ZHOU; D'EMANUELE, Antony; LENNON, Kieran et al.Macromolecules (Print). 2009, Vol 42, Num 20, pp 7936-7944, issn 0024-9297, 9 p.Article

Hepatitis C Infection and Thyrotoxic Periodic Paralysis : A Novel Use of an Old DrugTRAN, Huy A; REEVES, Glenn E.The American journal of the medical sciences (Print). 2008, Vol 336, Num 6, pp 515-518, issn 0002-9629, 4 p.Article

Effect of spironolactone on C-reactive protein levels in patients with heart diseaseGODFREY, Valerie; FARQUHARSON, Colin A. J; MACDONALD, John E et al.International journal of cardiology. 2007, Vol 117, Num 2, pp 282-284, issn 0167-5273, 3 p.Article

Effect of spironolactone on blood pressure in subjects with resistant hypertension. CommentaryGOODFRIEND, Theodore L; CHAPMAN, Neil; DOBSON, Joanna et al.Hypertension (Dallas, Tex. 1979). 2007, Vol 49, Num 4, issn 0194-911X, 763-764,839-845 [9 p.]Article

Mineralocorticoid receptor activation promotes vascular cell calcificationJAFFE, Iris Z; TINTUT, Yin; NEWFELL, Brenna G et al.Arteriosclerosis, thrombosis, and vascular biology. 2007, Vol 27, Num 4, pp 799-805, issn 1079-5642, 7 p.Article

Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. CommentaryKRAKOFF, Lawrence R; SHAH, Nimit C; PRINGLE, Stuart D et al.Journal of hypertension. 2007, Vol 25, Num 11, issn 0263-6352, 2207-2208, 2345-2351 [9 p.]Article